Nothaft Harald

Dr. Nothaft Harald

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2010 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
NHNothaft Harald
Nothaft Harald
CSChristine M. Szymanski
Christine M. Szymanski

1 March 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NHNothaft Harald
Nothaft Harald
CSChristine Szymanski
Christine Szymanski
Protein glycosylation is widespread throughout all three domains of life. Bacterial protein N-glycosylation and its application to engineering recombinant glycoproteins continue to be actively studied. Here, we focus on advances made in the last 2 years, including the characterization of novel bacterial N-glycosylation pathways, examination of pathway enzymes and evolution, biological roles of protein modification in the native host, and exploitation of the N-glycosylation pathways to create novel vaccines and diagnostics.

25 May 2016 in Scientific Reports
Verified
Journal Article
Open access
NHNothaft Harald
Nothaft Harald
BDBrandi Davis
Brandi Davis
YLYee Ying Lock
Yee Ying Lock
MPMaria Elisa Perez-Munoz
Maria Elisa Perez-Munoz
EVEvgeny Vinogradov
Evgeny Vinogradov
CSChristine Szymanski
Christine Szymanski
Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. coli-displayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycan-specific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain.

1 December 2017 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
NHNothaft Harald
Nothaft Harald
MPM. E. Perez-Muñoz
M. E. Perez-Muñoz
GGG. J. Gouveia
G. J. Gouveia
RDRebbeca Duar
Rebbeca Duar
JWJ. J. Wanford
J. J. Wanford
CSChristine Szymanski
Christine Szymanski
Source attribution studies report that the consumption of contaminated poultry is the primary source for acquiring human campylobacteriosis. Oral administration of an engineeredEscherichia colistrain expressing theCampylobacter jejuniN-glycan reduces bacterial colonization in specific-pathogen-free leghorn chickens, but only a fraction of birds respond to vaccination. Optimization of the vaccine for commercial broiler chickens has great potential to prevent the entry of the pathogen into the food chain. Here, we tested the same vaccination approach in broiler chickens and observed similar efficacies in pathogen load reduction, stimulation of the host IgY response, the lack ofC. jejuniresistance development, uniformity in microbial gut composition, and the bimodal response to treatment. Gut microbiota analysis of leghorn and broiler vaccine responders identified one member ofClostridialescluster XIVa,Anaerosporobacter mobilis, that was significantly more abundant in responder birds. In broiler chickens, coadministration of the live vaccine withA. mobilisorLactobacillus reuteri, a commonly used probiotic, resulted in increased vaccine efficacy, antibody responses, and weight gain. To investigate whether the responder-nonresponder effect was due to the selection of aC. jejuni“supercolonizer mutant” with altered phase-variable genes, we analyzed all poly(G)-containing loci of the input strain compared to nonresponder colony isolates and found no evidence of phase state selection. However, untargeted nuclear magnetic resonance (NMR)-based metabolomics identified a potential biomarker negatively correlated withC. jejunicolonization levels that is possibly linked to increased microbial diversity in this subgroup. The comprehensive methods used to examine the bimodality of the vaccine response provide several opportunities to improve theC. jejunivaccine and the efficacy of any vaccination strategy.IMPORTANCECampylobacter jejuniis a common cause of human diarrheal disease worldwide and is listed by the World Health Organization as a high-priority pathogen.C. jejuniinfection typically occurs through the ingestion of contaminated chicken meat, so many efforts are targeted at reducingC. jejunilevels at the source. We previously developed a vaccine that reducesC. jejunilevels in egg-laying chickens. In this study, we improved vaccine performance in meat birds by supplementing the vaccine with probiotics. In addition, we demonstrated thatC. jejunicolonization levels in chickens are negatively correlated with the abundance of clostridia, another group of common gut microbes. We describe new methods for vaccine optimization that will assist in improving theC. jejunivaccine and other vaccines under development.

1 December 2019 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
NHNothaft Harald
Nothaft Harald
CSChristine Szymanski
Christine Szymanski

1 July 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CWCory Q. Wenzel
Cory Q. Wenzel
DMDominic C. Mills
Dominic C. Mills
JDJustyna M. Dobruchowska
Justyna M. Dobruchowska
JVJiri Vlach
Jiri Vlach
NHNothaft Harald
Nothaft Harald
CSChristine Szymanski
Christine Szymanski
Clostridium perfringens is a leading cause of food-poisoning and causes avian necrotic enteritis, posing a significant problem to both the poultry industry and human health. No effective vaccine against C. perfringens is currently available. Using an antiserum screen of mutants generated from a C. perfringens transposon-mutant library, here we identified an immunoreactive antigen that was lost in a putative glycosyltransferase mutant, suggesting that this antigen is likely a glycoconjugate. Following injection of formalin-fixed whole cells of C. perfringens HN13 (a laboratory strain) and JGS4143 (chicken isolate) intramuscularly into chickens, the HN13-derived antiserum was cross-reactive in immunoblots with all tested 32 field isolates, whereas only 5 of 32 isolates were recognized by JGS4143-derived antiserum. The immunoreactive antigens from both HN13 and JGS4143 were isolated, and structural analysis by MALDI-TOF-MS, GC-MS, and 2D NMR revealed that both were atypical lipoteichoic acids (LTAs) with poly-(β1→4)-ManNAc backbones substituted with phosphoethanolamine. However, although the ManNAc residues in JGS4143 LTA were phosphoethanolamine-modified, a few of these residues were instead modified with phosphoglycerol in the HN13 LTA. The JGS4143 LTA also had a terminal ribose and ManNAc instead of ManN in the core region, suggesting that these differences may contribute to the broadly cross-reactive response elicited by HN13. In a passive-protection chicken experiment, oral challenge with C. perfringens JGS4143 lead to 22% survival, whereas co-gavage with JGS4143 and α-HN13 antiserum resulted in 89% survival. This serum also induced bacterial killing in opsonophagocytosis assays, suggesting that HN13 LTA is an attractive target for future vaccine-development studies.